A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) (MODIFY I)

Clinical Trial ID NCT01241552

Rank	Title	Journal	Year	PubWeight™‹?›
1	Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.	N Engl J Med	2017	4.68
2	Antibodies to watch in 2015.	MAbs	2015	1.28
3	Antibodies to watch in 2016.	MAbs	2015	1.17
4	A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.	Clin Vaccine Immunol	2013	1.03
5	A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile.	Microbiology	2013	1.02
6	Antibodies for treatment of Clostridium difficile infection.	Clin Vaccine Immunol	2014	0.87
7	Clostridium difficile drug pipeline: challenges in discovery and development of new agents.	J Med Chem	2015	0.86
8	Immune-based treatment and prevention of Clostridium difficile infection.	Hum Vaccin Immunother	2014	0.84
9	Emerging therapies for Clostridium difficile infection - focus on fidaxomicin.	Infect Drug Resist	2013	0.79
10	Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.	Curr Top Med Chem	2014	0.79
11	IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA.	MAbs	2013	0.78
12	Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach.	BMC Infect Dis	2016	0.78